Vaxcyte, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
August 11, 2021 at 04:07 pm EDT
Share
Vaxcyte, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported loss from operation of $23,730,000 against $21,224,000 a year ago. Net loss was $23,679,000 against $20,320,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.46 against $1.72 a year ago.
For the six months, the company reported loss from operation of $46,873,000 against $48,820,000 a year ago. Net loss was $44,899,000 against $47,462,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.87 against $5.99 a year ago.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
VAXCYTE, INC. 
